

<b>FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT</b>					<b>SERIAL NO.</b>	<b>09/493,480</b>	
					<b>FILING DATE</b>	<b>January 28, 2000</b>	
					<b>APPLICANT</b>	<b>Cheever et al.</b>	
					<b>GROUP</b>	<b>1643</b>	
					<b>EXAMINER</b>	<b>A. Holleran</b>	
					<b>ATTORNEY DOCKET NO.</b>	<b>CRX113US</b>	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
ALH	1.	5,801,005	9/1/1998	Cheever et al.			
ALH	2.	5,976,546	11/2/1999	Laus et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
ALH	3.	BERNHARD et al., Vaccination against the HER-2/nu oncogenic protein, Endocrine-Related Cancer 9:33-44 (2002).					
ALH	4.	CHAMBERLAIN and KAUFMAN, Innovations and strategies for the development of anticancer vaccines, Expert Opinion on Pharmacotherapy 1(4):603-614 (2000).					
EXAMINER				/Anne Holleran/ (01/07/2007)		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							